Features of TP53-mutated patients with chronic myelomonocytic leukemia in a national (ABCMML) and international cohort (cBIOPORTAL).

IF 1.1 Q2 MEDICINE, GENERAL & INTERNAL

Wiener medizinische Wochenschrift Pub Date : 2025-03-05 DOI:10.1007/s10354-025-01072-0

Magdalena Grass, Klaus Geissler

{"title":"Features of TP53-mutated patients with chronic myelomonocytic leukemia in a national (ABCMML) and international cohort (cBIOPORTAL).","authors":"Magdalena Grass, Klaus Geissler","doi":"10.1007/s10354-025-01072-0","DOIUrl":null,"url":null,"abstract":"<p><p>Big data collected in large international cooperations allow validation of findings from traditional national patient cohorts for proving consistency. In this study we analyzed outcomes and phenotypic features of TP53-mutated chronic myelomonocytic leukemia (CMML) patients in the Austrian biodatabase for CMML (ABCMML; n = 322) and in the international platform cBIOPORTAL (n = 399). The prevalences of TP53 mutations were 1.58 and 3.66, respectively. Numerically, overall survival was shorter in TP53-mutated patients in both cohorts (ABCMML 10.0 vs. 30.0 months and cBIOPORTAL 8.9 vs. 34.5 months), but this was statistically significant only in the cBIOPORTAL cohort. Decreased hemoglobin values and the presence of blast cells in peripheral blood were significantly associated with TP53 mutations in the cBIOPORTAL group but not in the ABCMML database. Our study indicates the necessity of sufficient patient numbers for the comparison of CMML patients regarding outcome and phenotype according to their molecular subtype, particularly in the case of rare mutations.</p>","PeriodicalId":23882,"journal":{"name":"Wiener medizinische Wochenschrift","volume":" ","pages":""},"PeriodicalIF":1.1000,"publicationDate":"2025-03-05","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":"0","resultStr":null,"platform":"Semanticscholar","paperid":null,"PeriodicalName":"Wiener medizinische Wochenschrift","FirstCategoryId":"1085","ListUrlMain":"https://doi.org/10.1007/s10354-025-01072-0","RegionNum":0,"RegionCategory":null,"ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":null,"EPubDate":"","PubModel":"","JCR":"Q2","JCRName":"MEDICINE, GENERAL & INTERNAL","Score":null,"Total":0}

引用次数: 0

Abstract

Big data collected in large international cooperations allow validation of findings from traditional national patient cohorts for proving consistency. In this study we analyzed outcomes and phenotypic features of TP53-mutated chronic myelomonocytic leukemia (CMML) patients in the Austrian biodatabase for CMML (ABCMML; n = 322) and in the international platform cBIOPORTAL (n = 399). The prevalences of TP53 mutations were 1.58 and 3.66, respectively. Numerically, overall survival was shorter in TP53-mutated patients in both cohorts (ABCMML 10.0 vs. 30.0 months and cBIOPORTAL 8.9 vs. 34.5 months), but this was statistically significant only in the cBIOPORTAL cohort. Decreased hemoglobin values and the presence of blast cells in peripheral blood were significantly associated with TP53 mutations in the cBIOPORTAL group but not in the ABCMML database. Our study indicates the necessity of sufficient patient numbers for the comparison of CMML patients regarding outcome and phenotype according to their molecular subtype, particularly in the case of rare mutations.

查看原文本刊更多论文

求助全文

约1分钟内获得全文求助全文

来源期刊

Wiener medizinische Wochenschrift MEDICINE, GENERAL & INTERNAL-

CiteScore

2.50

自引率

0.00%

发文量

期刊介绍： ''From the microscope to clinical application!'', Scientists from all European countries make available their recent research results and practical experience through Wiener Medizinische Wochenschrift, the renowned English- and German-language forum. Both original articles and reviews on a broad spectrum of clinical and preclinical medicine are presented within the successful framework of thematic issues compiled by guest editors. Selected cutting-edge topics, such as dementia, geriatric oncology, Helicobacter pylori and phytomedicine make the journal a mandatory source of information.